Abstract
A total of 23 women with stage II breast cancer receiving adjuvant cyclophosphamide, methotrexate and 5-fluorouracil had detailed pharmacokinetic monitoring performed on the first and third courses of therapy. The area under the concentration time curve (AUC) of each of these three drugs varied by a factor of 3–4 among patients. No systematic change in pharmacokinetics between the first and third courses was seen for cyclophosphamide, methotrexate or 5-fluorouracil, and the mean AUC for each of the three drugs did not change. However, significant intrapatient variability in drug pharmacokinetics was observed for all three drugs such that the AUC, clearance and half-life in an individual on the third course could not be reliably predicted from data generated on the first course. On the basis of these results, cyclophosphamide, methotrexate, and 5-fluorouracil pharmacokinetic data from one treatment would not be useful information from which the doses for subsequent courses could be determined.
Similar content being viewed by others
References
Bonadonna G, Valagussa P (1981) Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10
Bonadonna G (1989) Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7: 1380
Burkputt AR, Boyd MR (1980) Measurement of 5-fluorouracil in plasma by HPLC. Ann Biochem 106: 432
D'Argenio DZ, Schumitsky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Methods Programs Biomed 9: 115
Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215
Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA (1989) A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 49: 3129
Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing scheme for the cisplatin analogue diamminecyclo-butanedicarboxylatoplatinum. Cancer Res 45: 6502
Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York
Hardy RW, Erlichman C, Soldin SJ (1984) High-performance liquid chromatographic measurement of cyclophosphamide in plasma. Ther Drug Monit 6:313
Henderson IC, Hayes DF, Gelman R (1988) Dose response in the treatment of breast cancer: a critical review. J Clin Oncol 6: 1501
Hryniuk W, Levine L (1986) Dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162
Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094
Kerr IG, Jolivet J, Collins JM, Drake JC, Chabner BA (1983) Test dose for predicting high dose methotrexate infusions. Clin Pharmacol Ther 33: 44
Milano G, Roman P, Ishter R, Prenay M, Renee N, Namer M (1988) Dose versus pharmacokinetics for predicting tolerance to 5 day cotinuous infusion of 5-fluorouracil. Int J Cancer 41: 537
Moore M (1991) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20: 194
Moore MJ, Erlichman C (1987) Therapeutic drug monitoring in oncology. Clin Pharmacokinet 13: 205
Slee PH, DeBruijn EA, Dreissen OM, Oosterom AT van (1983) Pharmacokinetics of the cytostatic drugs used in the CMF regimen. Anticancer Res 3: 269
Author information
Authors and Affiliations
Additional information
This research was supported by the National Cancer Institute of Canada
Rights and permissions
About this article
Cite this article
Moore, M.J., Erlichman, C., Thiessen, J.J. et al. Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother. Pharmacol. 33, 472–476 (1994). https://doi.org/10.1007/BF00686503
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686503